DBC1, a novel native inhibitor of anti-aging protein SIRT1

US8043804B2 · kind B2 · utility

Assignee

• The Trustees of Columbia University in the City of New York · US

Inventor

• Wei Gu · Zhejiang, CN

Key dates

• Filing date: May 23, 2008
• Grant date: Oct 25, 2011
• Expiry date: Sep 6, 2028

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2500/02
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

A novel complex is identified between the NAD-dependent deacetylase, SIRT1 and its novel inhibitor, DBC1. Provided herein are methods to identify a compound that inhibits the complexation between SIRT1 and DBC1. Exemplary methods comprise contacting either the complexation between DBC1 and SIRT1 with an agent being tested for its ability to inhibit the complexation between SIRT1 and DBC1. Also, provided are methods to identify a compound that increases the complexation between SIRT1 and DBC1. Exemplary methods comprise contacting either the complexation between DBC1 and SIRT1 with an agent being tested for its ability to increase the complexation between SIRT1 and DBC1. Further, methods are provided to increase or decrease SIRT1 activity by contacting the complexation between SIRT1 and DBC1 with a peptide that either decreases or increases the complexation between SIRT1 and DBC1. Further, methods are provided for the treatment of patients suffering from diseases including metabolic diseases including obesity and diabetes, and neurodegenerative disorders including Alzheimer's disease and Huntington's disease using compounds that inhibit the complexation between SIRT1 and DBC1.